公开(公告)号：US20230113516A1

公开(公告)日：2023-04-13

申请号：US17913687

申请日：2021-03-24

申请人： Metriopharm AG

发明人： Wolfgang Brysch ,  Astrid Kaiser ,  Petra Schulz ,  Sara Schumann ,  Jörg von Wegerer ,  Christian Setz ,  Ulrich Schubert

IPC分类号： A61K31/502 ,  A61K45/06 ,  A61P11/00

摘要： The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts in the prevention or treatment of acute lung injury. The invention in particular relates to the use of 5-amino-2, 3-dihydro-1,4-phthalazinedione sodium salt for said purposes.

公开(公告)号：US20230061223A1

公开(公告)日：2023-03-02

申请号：US17795360

申请日：2021-01-29

申请人： MetrioPharm AG

发明人： Wolfgang Brysch ,  Astrid Kaiser ,  Petra Schulz ,  Sara Schumann ,  Jörg von Wegerer

IPC分类号： A61K9/00 ,  A61P11/00 ,  A61K31/502 ,  A61M11/00

摘要： The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or its pharmaceutically acceptable N salts in the inhalatory treatment of inflammatory pulmonary diseases. The invention in particular relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for said purposes. Advantageous features of an aerosol containing 5-amino-2,3-dihydro-1,4-phthalazinedione or its pharmaceutically acceptable salts and a method for producing said aerosol are disclosed. The present invention further relates to a kit for inhalatory treatment of inflammatory pulmonary diseases.

公开(公告)号：US20230053455A1

公开(公告)日：2023-02-23

申请号：US17791460

申请日：2021-01-29

申请人： Metriopharm AG

发明人： Wolfgang Brysch ,  Astrid Kaiser ,  Petra Schulz ,  Sara Schumann ,  Jörg von Wegerer

IPC分类号： A61K31/502 ,  A61P11/00

摘要： The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts in the treatment of rare chronic inflammatory pulmonary diseases. The invention in particular relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for said purposes.

公开(公告)号：US11007192B2

公开(公告)日：2021-05-18

申请号：US16347171

申请日：2017-11-06

申请人： METRIOPHARM AG

发明人： Wolfgang Brysch ,  Astrid Kaiser ,  Claudia Van Laak ,  Beate Ludescher ,  Maliha Shah ,  Jörg Von Wegerer

IPC分类号： A61K31/502 ,  A61K9/00 ,  A61P25/28

摘要： The invention relates to 5-amino-2,3-dihydro-1,4-phthalazinedione or related compounds, compositions or combinations thereof, for use in the treatment of chronic progressive multiple sclerosis, in particular primary and secondary progressive multiple sclerosis. The invention in particular relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for said purposes.

公开(公告)号：US09079863B2

公开(公告)日：2015-07-14

申请号：US14247626

申请日：2014-04-08

申请人： METRIOPHARM AG

发明人： Josef Breu ,  Wolfgang Brysch ,  Astrid Kaiser ,  Beate Ludescher ,  Gerrit Maass ,  Thomas Martin ,  Wolfgang Milius ,  Michael Niedermaier

IPC分类号： C07D237/30 ,  A61K31/50 ,  A01N43/58 ,  C07D237/32

CPC分类号： C07D237/32

摘要： The invention relates to the provision of two novel crystalline forms I and II for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt. Surprisingly, it was discovered that form I and form II have differing immunological effects. This advantageous property is useful for immunospecific applications. In addition, both forms have advantageous physicochemical properties, which are useful in the production, further processing and/or use of a pharmaceutical preparation of form I or form II or a mixture of both.

摘要翻译： 本发明涉及为5-氨基-2,3-二氢酞嗪-1,4-二酮钠盐提供两种新的结晶形式I和II。 令人惊讶的是，发现I型和II型具有不同的免疫学作用。 这种有利的性质可用于免疫特异性应用。 此外，两种形式都具有有利的物理化学性质，其可用于生产，进一步加工和/或使用I型或II型药物制剂或两者的混合物。